Share This Article:

Association of adverse effects with monoamine oxidase type B inhibitor and catechol-o-methyl transferase inhibitor combination therapy in Parkinson’s disease patients

Abstract Full-Text HTML Download Download as PDF (Size:208KB) PP. 5-10
DOI: 10.4236/apd.2012.11002    3,645 Downloads   6,506 Views   Citations

ABSTRACT

Currently, levodopa is the most effective and commonly used medication to control motor symptoms in Parkinson’s disease (PD). However, its long-term use is associated with adverse effects (AEs). Combination therapy of a monoamine oxidase type B inhibitor (MAOBI) with levodopa or a catechol-O-methyl transferase inhibitor (COMTI) with levodopa provides benefits to PD patients. Direct comparison of efficacy and side effect profiles is complex. The aim of this study is to investigate the different AE profiles of MAOBI and COMTI combination therapies. Data used to analyze the AEs of different PD medications were retrieved from “The Boston University Medical Center’s Parkinson’s Disease and Movement Disorder Database”. Ten categories of AEs were compared between patients receiving MAOBI and COMTI combination treatment. In total, 87 subjects were included in the analysis. Out of ten AEs, the presence of dementia was signifi- cantly different between the MAOBI and COMTI groups with an OR of 6.9 (COMTI vs MAOBI, 95% CI 1.3 - 37.0). Motor fluctuations were also found to be differently distributed in the two medication groups with an OR of 3.1 (COMTI vs MAOBI, 95% CI 1.0 - 9.8). In this retrospective database analysis of patients treated with combination treatment for PD, combination therapy of a COMTI with levodopa was more likely to be associated with dementia and motor fluctuations than a MAOBI with levodopa.

Conflicts of Interest

The authors declare no conflicts of interest.

Cite this paper

Zhang, R., Spengler, D., Saint-Hilaire, M. and Hohler, A. (2012) Association of adverse effects with monoamine oxidase type B inhibitor and catechol-o-methyl transferase inhibitor combination therapy in Parkinson’s disease patients. Advances in Parkinson's Disease, 1, 5-10. doi: 10.4236/apd.2012.11002.

References

[1] Dewey Jr., R.B. (2004) Management of motor complications in Parkinson’s disease. Neurology, 62, S3-S7. doi:10.1212/WNL.62.6_suppl_4.S3
[2] Hoehn, M.M. and Yahr, M.D. (1967) Parkinsonism: Onset, progression and mortality. Neurology, 17, 427-442. doi:10.1212/WNL.17.5.427
[3] Parkinson, N.J., Robin, C., Newton, J. R., Slater, J. and Waller, A.S. (2011) Molecular epidemiology of strangles outbreaks in the UK during 2010. Veterinary Record, 168, 666. doi:10.1136/vr.d1485
[4] Wirdefeldt, K., Adami, H.O., Cole, P., Trichopoulos, D. and Mandel, J. (2011) Epidemiology and etiology of Parkinson’s disease: A review of the evidence. European Journal of Epidemiology, 26, S1-S58. doi:10.1007/s10654-011-9581-6
[5] Henchcliffe, C. and Beal, M.F. (2007) Pathogenesis: Oxidative stress, mitochodrial dysfunction, and excito-toxicity. In: Factor, S.A. and Weiner, W.J., Eds., Parkinson’s Disease Diagnosis & Clinical Management, 2nd Edition, Demos Medical Publishing, New York, 341-356.
[6] Jankovic, J. and Stacy, M. (2007) Medical management of levodopaassociated motor complications in patients with Parkinson’s disease. CNS Drugs, 21, 677-692. doi:10.2165/00023210-200721080-00005
[7] Schwid, S.R., Shoulson, I., Stern, M., Oakes, D., Kieburtz, K., Fahn, S., et al. (2005) A randomized placebo-controlled trial of rasagiline in levodopatreated patients with Parkinson disease and motor fluctuations: The PRESTO study. Archives of Neurology, 62, 241-248. doi:10.1001/archneur.62.2.241
[8] Simuni, T., Hurtig, H., Adler, C.H., Rajput, A., Zesiewicz, T.A., Hauser, R.A., et al. (2007) Drugs. In: Factor, S.A. and Weiner, W.J., Eds., Parkinson’s Disease Diagnosis & Clinical Management, Demos Medical Publishing, New York, 471-571.
[9] Smith, L.P. (2003) Steady the course of Parkinson’s disease. Nurs Manage, 34, 35-39. doi:10.1097/00006247-200304000-00011
[10] Solla, P., Cannas, A., Marrosu, F. and Marrosu, M.G. (2010) Therapeutic interventions and adjustments in the management of Parkinson disease: Role of combined carbidopa/levodopa/entacapone (Stalevo). Journal of Neu-ropsychiatric Disease and Treatment, 6, 483-490. doi:10.2147/NDT.S5190
[11] Tarrants, M.L., Denarie, M.F., Castelli-Haley, J., Millard, J. and Zhang, D. (2010) Drug therapies for Parkinson’s disease: A database analysis of patient compliance and persistence. American Journal of Geriatric Pharmaco-therapy, 8, 374-383. doi:10.1016/j.amjopharm.2010.08.001
[12] Gardian, G. and Vecsei, L. (2010) Medical treatment of Parkinson’s disease: Today and the future. International Journal of Clinical Pharmacology, Therapy, 48, 633-642.
[13] Caslake, R., Macleod, A., Ives, N., Stowe, R. and Counsell, C. (2009) Monoamine oxidase B inhibitors versus other dopaminergic agents in early Parkinson’s disease. Cochrane Database of Systematic Reviews, 4, CD006661.
[14] Stowe, R., Ives, N., Clarke, C. E., Deane, K., Wheatley, K., Gray, R., et al. (2010) Evaluation of the efficacy and safety of adjuvant treatment to levodopa therapy in Parkinson s disease patients with motor complications. Cochrane Database of Systematic Reviews, 7, CD007166.
[15] Myllyla, V.V., Sotaniemi, K.A., Vuorinen, J.A. and Heinonen, E.H. (1993) Selegiline in de novo parkinsonian patients: The Finnish study. Movement Disorders, 8, S41- S44. doi:10.1002/mds.870080509
[16] Parkinson Study Group (2005) A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: The PRESTO study. Archives of Neurology, 62, 241-248. doi:10.1001/archneur.62.2.241
[17] Sivertsen, B., Dupont, E., Mikkelsen, B., Mogensen, P., Rasmussen, C., Boesen, F., et al. (1989) Selegiline and levodopa in early or moderately advanced Parkinson’s disease: A double-blind controlled short-and long-term study. Acta Neurologica Scandinavica, Supplementum, 126, 147-152. doi:10.1111/j.1600-0404.1989.tb01794.x
[18] Boyson, S.J. (1991) Psychiatric effects of selegiline. Archives of Neurology, 48, 902. doi:10.1001/archneur.1991.00530210028017
[19] Kurlan, R and Dimitsopulos, T. (1992) Selegiline and manic behavior in Parkinson’s disease. Archives of Neurology, 49, 1231. doi:10.1001/archneur.1992.00530360029012
[20] Talati, R., Reinhart, K., Baker, W., White, C.M. and Coleman, C.I. (2009) Pharmacologic treatment of advanced Parkinson’s disease: A meta-analysis of COMT inhibitors and MAO-B inhibitors. Parkinsonism & Related Disorders, 15, 500-505. doi:10.1016/j.parkreldis.2008.12.007
[21] Kurth, M.C. and Adler, C.H. (1998) COMT inhibition: A new treatment strategy for Parkinson’s disease. Neurology, 50, S3-S14. doi:10.1212/WNL.50.5_Suppl_5.S3
[22] Adler, C.H., Singer, C., O’Brien, C., Hauser, R.A., Lew, M.F., Marek, K.L., et al. (1998) Randomized, placebo- controlled study of tolcapone in patients with fluctuating Parkinson disease treated with levodopa-carbidopa. Tol-capone Fluctuator Study Group III. Archives of Neurology, 55, 1089-1095. doi:10.1001/archneur.55.8.1089
[23] Brooks, D.J., Leinonen, M., Kuoppamaki, M. and Nissinen, H. (2008) Five-year efficacy and safety of levodopa/ DDCI and entacapone in patients with Parkinson’s disease. Journal of Neural Transmission, 115, 843-849. doi:10.1007/s00702-008-0025-8
[24] Kurth, M.C., Adler, C.H., Saint-Hilaire, M., Singer, C., Waters, C., LeWitt, P., et al. (1997) Tolcapone improves motor function and reduces levodopa requirement in patients with Parkinson’s disease experiencing motor fluctuations: A multicenter, double-blind, randomized, place-bo-controlled trial. Tolcapone Fluctuator Study Group I. Neurology, 48, 81-87. doi:10.1212/WNL.48.1.81
[25] Parkinson Study Group (1997) Entacapone improves motor fluctuations in levodopa-treated Parkinson’s disease patients. Parkinson Study Group. Annals of Neurology, 42, 747-755.
[26] Rajput, A.H., Martin, W., Saint-Hilaire, M.H., Dorflinger, E. and Pedder, S. (1997) Tolcapone improves motor function in parkinsonian patients with the “wearing-off” phenomenon: A double-blind, placebo-controlled, multicenter trial. Neurology, 49, 1066-1071. doi:10.1212/WNL.49.4.1066
[27] Rascol, O., Brooks, D.J., Melamed, E., Oertel, W., Poewe, W., Stocchi, F., et al. (2005) Rasagiline as an adjunct to levodopa in patients with Parkinson’s disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): A randomised, double-blind, parallel-group trial. Lancet, 365, 947-954. doi:10.1016/S0140-6736(05)71083-7
[28] Hemming, J.P., Gruber-Baldini, A.L., Anderson, K.E., Fishman, P.S., Reich, S.G., Weiner, W.J., et al. (2011) Racial and socioeconomic disparities in parkinsonism. Archives of Neurology, 68, 498-503. doi:10.1001/archneurol.2010.326
[29] Van Den Eeden, S.K., Tanner, C.M., Bernstein, A.L., Fross, R.D., Leimpeter, A., Bloch, D.A., et al. (2003) Incidence of Parkinson’s disease: Variation by age, gender, and race/ethnicity. American Journal of Epidemiology, 157, 1015-1022. doi:10.1093/aje/kwg068
[30] Marder, K.S. and Jacobs, D.M. (2007) Dementia. In: Factor, S.A. and Weiner, W.J., Eds., Parkinson’s Disease Diagnosis & Clinical Management, Demos Medical Publishing, New York.
[31] Aarsland, D., Andersen, K., Larsen, J.P., Lolk, A., Nielsen, H.and Kragh-Sorensen, P. (2001) Risk of dementia in Parkinson’s disease: A community-based, prospective study. Neurology, 56, 730-736. doi:10.1212/WNL.56.6.730
[32] Hughes, T.A., Ross, H.F., Musa, S., Bhattacherjee, S., Nathan, R.N., Mindham, R.H., et al. (2000) A 10-year study of the incidence of and factors predicting dementia in Parkinson’s disease. Neurology, 54, 1596-1602.
[33] Gunzler, S.A. and Nutt, J.G. (2007) Motor fluctuations and dyskinesia. In: Factor, S.A. and Weiner, W.J., Eds., Parkinson’s Disease Diagnosis & Clinical Management, Demos Medical Publishing, New York.

  
comments powered by Disqus

Copyright © 2018 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.